Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals
NYSE | Common Stock
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally.
The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.
It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic.
The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution.
It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies.
The company was incorporated in 1959 and is based in Haifa, Israel.
Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt.
As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 20, 24 | 0.40 Increased by +122.22% | 0.31 Increased by +29.03% |
| Jan 25, 24 | 0.54 Increased by +184.21% | 0.30 Increased by +80.00% |
| Oct 26, 23 | 0.38 Increased by +642.86% | 0.18 Increased by +111.11% |
| Jul 26, 23 | 0.40 Increased by +8.11% | 0.31 Increased by +29.03% |
| May 23, 23 | 0.18 Decreased by -75.34% | 0.23 Decreased by -21.74% |
| Jan 24, 23 | 0.19 Decreased by -72.86% | 0.87 Decreased by -78.16% |
| Oct 27, 22 | -0.07 Decreased by -110.61% | 0.84 Decreased by -108.33% |
| Jul 27, 22 | 0.37 Decreased by -66.06% | 0.85 Decreased by -56.47% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 164.94 M Increased by +12.52% | 15.08 M Increased by +118.11% | Increased by +9.14% Increased by +93.84% |
| Dec 31, 23 | 157.15 M Increased by +12.89% | 20.21 M Increased by +178.16% | Increased by +12.86% Increased by +146.40% |
| Sep 30, 23 | 148.20 M Increased by +13.57% | 8.55 M Increased by +403.84% | Increased by +5.77% Increased by +367.54% |
| Jun 30, 23 | 158.89 M Increased by +1.42% | 10.03 M Decreased by -28.74% | Increased by +6.31% Decreased by -29.74% |
| Mar 31, 23 | 146.59 M Increased by +2.32% | 6.91 M Decreased by -74.77% | Increased by +4.72% Decreased by -75.35% |
| Dec 31, 22 | 139.20 M Increased by +0.16% | 7.26 M Decreased by -72.39% | Increased by +5.22% Decreased by -72.43% |
| Sep 30, 22 | 130.50 M Decreased by -1.13% | -2.81 M Decreased by -112.06% | Decreased by -2.16% Decreased by -112.20% |
| Jun 30, 22 | 156.66 M Increased by +6.49% | 14.08 M Increased by +175.02% | Increased by +8.99% Increased by +170.45% |